

Cytokine storm and translating IL-6 biology into effective treatments for COVID-19

Tiantian Li¹, Dongsheng Wang², Haiming Wei^{3,4}, Xiaoling Xu (✉)²

¹Department of Geriatric Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; ²Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; ³Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230001, China; ⁴Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei 230001, China

© Higher Education Press 2023

Abstract As of May 3, 2023, the coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 760 million confirmed cases and over 6.9 million deaths. Several patients have developed pneumonia, which can deteriorate into acute respiratory distress syndrome. The primary etiology may be attributed to cytokine storm, which is triggered by the excessive release of proinflammatory cytokines and subsequently leads to immune dysregulation. Considering that high levels of interleukin-6 (IL-6) have been detected in several highly pathogenic coronavirus-infected diseases, such as severe acute respiratory syndrome in 2002, the Middle East respiratory syndrome in 2012, and COVID-19, the IL-6 pathway has emerged as a key in the pathogenesis of this hyperinflammatory state. Thus, we review the history of cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab in combating COVID-19.

Keywords SARS-CoV-2; COVID-19; cytokine storm; interleukin-6; tocilizumab

Introduction

At the end of 2019, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) initiated a global epidemic of a human-to-human pandemic disease, which was named as coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) [1]. Unprecedented difficulties have been posed to the global healthcare system by this pandemic. Up to May 3, 2023, there were 765 222 932 confirmed cases of COVID-19 worldwide with a reported death toll of 6 921 614 as on statistics made public by the WHO [2]. The median incubation after SARS-CoV-2 infection is 4 days [3]. Over 80% of individuals have mild disease, and clinical symptoms might vary in severity [4,5]. Considering that SARS-CoV-2 primarily targets the upper respiratory tract, most patients report symptoms like sore throat, dry cough, and fever [3,6–8]. Invading the lower respiratory tract can cause acute lung damage and can induce acute respiratory

distress syndrome (ARDS) within a median period of 8 days from disease onset [8]. These conditions are detected in chest computed tomographic images as bilateral patchy shadows or ground glass opacity [9–11]. SARS-CoV-2 gains entry into host cells through the angiotensin-converting enzyme 2 receptor, which confers the virus with the potential to invade various organs and systems. Zou *et al.* constructed a risk map indicating the potential risk of different organs to SARS-CoV-2 infection [12]. The reported symptoms and complications encompass olfactory and gustatory dysfunctions, anorexia, nausea or vomiting, diarrhea, heart palpitations, myocardial injury, heart failure, liver dysfunction, kidney injury, thrombosis, myalgia or arthralgia, headache, fatigue, stroke, mental disorders, conjunctival congestion, and ocular pain [3,6,8,13–30]. The conditions may progress rapidly to varying degrees of dyspnea, septic shock, disseminated intravascular coagulation (DIC), uncorrectable metabolic acidosis, and multi-organ failure requiring admission to an intensive care unit (ICU) [31]. These conditions are associated with poor prognosis and high mortality rates.

Patients admitted to an ICU exhibit an increased level of interleukin (IL) 2, IL-7, IL-10, interferon- γ -inducible

Received May 15, 2023; accepted October 23, 2023

Correspondence: Xiaoling Xu, xlahh08@163.com or xlahh8@ustc.edu.cn

protein 10 (IP10), granulocyte-colony-stimulating factor (G-CSF), tumor necrosis factor α (TNF- α), monocyte chemoattractant protein 1 (MCP1), and macrophage inflammatory protein 1 alpha (MIP1A) compared with non-ICU patients [7]. In addition, Yang *et al.* found that IL-1 α , IL-6, macrophage-colony-stimulating factor (M-CSF), IP10, MCP-3, MIP1 α , hepatocyte growth factor, and monokine-induced gamma IFN were highly expressed in patients with critical and severe COVID-19 [32]. Lymphocytopenia was observed in most patients, and this condition exhibited a considerable correlation with disease severity [3,6–8,13,33–35]. An autopsy report from COVID-19 that progressed to ARDS revealed the presence of lymphocyte-dominant interstitial mononuclear inflammatory infiltrates in both lungs [36]. Zhou *et al.* performed immune analysis on peripheral blood samples obtained from patients with severe COVID-19 and identified heightened levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-6 [33]. These investigations have revealed that patients with COVID-19 experience a cytokine storm, indicating that blocking the inflammatory storm could serve as an efficacious treatment for severe COVID-19.

By competitively inhibiting the binding of IL-6 to its receptors, tocilizumab effectively blocks the signal transduction pathways mediated by IL-6. The US Food and Drug Administration (FDA) has approved the treatment of rheumatologic conditions [37–39] and cytokine storm associated with chimeric antigen receptor T cell therapy [40–42]. Considering the benefits of clinical trials, tocilizumab was granted emergency approval by the FDA on June 24, 2021, for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years old and above) who were receiving systemic corticosteroid therapy and requiring oxygen therapy, mechanical ventilation, or extracorporeal membrane oxygenation [43]. The WHO also strongly recommended the use of tocilizumab in patients with severe or critical COVID-19 on July 6, 2021 [44]. This review aims to investigate the role of cytokines in COVID-19 pathogenesis, providing comprehensive understanding of viral-induced inflammatory storm and exploring the efficacy and global application of tocilizumab as a treatment.

Cytokine storm

Cytokine storm pathology

Cytokines are a complex group of small proteins that are secreted by cells for signal transduction, including IL, chemokines, TNF, CSF, and interferon (IFN). They play a pivotal role in regulating immune and inflammatory responses [45–47]. The immune system, comprising innate and adaptive immunity, induces and activates the

release of cytokines to eliminate pathogens and restore immune homeostasis in response to foreign invaders. However, the excessive activation of cytokines disrupts the balance between anti-inflammatory and pro-inflammatory responses, causing hyperinflammation responses and multi-organ failure, which is known as cytokine storm [46,48]. This concept was first proposed in 1993 by Ferrara *et al.* [49] and then appeared more frequently in scientific research. Cytokine storm can be induced by a diverse range of infectious and non-infectious etiologies, encompassing various therapeutic interventions, pathogens, cancers, autoimmune disorders, and monogenic disorders [48].

In sensing invading viruses, the innate immune system serves as the first line of defense by recognizing and responding to pathogen-associated molecular pattern molecules through cytoplasmic pattern recognition receptors, thereby initiating the expression of IFN, the activation of antiviral cells, and the release of pro-inflammatory cytokines [50,51]. These processes subsequently trigger the activation of the adaptive immune system for combating infections [52]. The immune cells serve as vigilant guardians of the body safeguarding it against damaged cells and infectious agents, while mediating the inflammatory response by inducing the secretion of cytokines and chemokines. Excessive inflammatory innate responses in conjunction with impaired adaptive immune responses can result in tissue damage [53]. The innate immune cells predominantly involved in cytokine storm include neutrophils, macrophages, mast cells, and natural killer (NK) cells [54]. Neutrophils play a pivotal role in thrombosis and enhance cytokine production during cytokine storm [55]. Macrophages can induce severe tissue and organ damage by secreting excessive amounts of cytokines, and their activation by IFN- γ results in the consumptive anemia of inflammation [56]. Mast cells may release histamine to increase the production of IL-1 [57]. In addition, SARS-CoV-2 triggers the activation of alveolar macrophages through Toll-like receptors (TLRs), leading to IL-1 production, which in turn stimulates mast cells to secrete IL-6. As a prominent pro-inflammatory cytokine in cytokine storm, IL-1 plays a vital role in acute inflammatory responses by recruiting immune cells and inducing secondary cytokine production [58]. Elevated levels of IL-1 may be associated with the pathogenesis of systemic inflammation, coagulation disorders, and thrombotic complications [59,60]. SARS-CoV-2 can activate mast cells through TLRs, thereby inducing the release of proinflammatory mediators and triggering a cytokine storm that disrupts the blood–brain barrier and facilitates viral entry into the brain [61]. Increased inflammatory mediators may cause the activation of glial cells and neuron, and cause stroke, neuroinflammation, neurodegeneration, cognitive dysfunction, and neuronal

death. In addition, an article has suggested that an inflammatory immunoreactivity occurs in glioma and glioblastoma [62]. NK cells can kill infected cells and secrete regulatory cytokines; however, their cytolytic function is ineffective in some forms of cytokine storm [63]. Excessive levels of IL-6 may inhibit the function of NK cells, resulting in prolonged antigen stimulation and hindering the resolution of inflammation [64]. T cell-mediated adaptive immune responses play a pivotal role in viral clearance and long-term antiviral immunity; however, they may contribute to the development of cytokine storm. Type 1 helper T (Th1) cells, Th2 cells, Th9 cells, and Th17 cells can recruit macrophages, eosinophil, basophils, mast cells, and neutrophils to initiate inflammatory responses [65–67]. In addition, cytotoxic T lymphocytes are essential for the control of viral infections. After SARS-CoV-2 infection, the increased release of IL-6 and IL-10 was shown to upregulate the expression level of NKG2A on CD8 T cells, which curbs the expansion of CD8 T cells and leads to the functional exhaustion of cytotoxic lymphocytes associated with disease progression [68,69].

Through systemic circulation, the inflammation induced by cytokine storm travels broadly throughout the body from its localized origin [46]. Fever is a common manifestation observed in most patients. In addition, patients may experience respiratory symptoms (e.g., cough, sputum, dyspnoea), fatigue, gastrointestinal reactions, headache, rash, arthralgia, myalgia, and neuropsychiatric symptoms [70,71]. The repair process begins shortly after the onset of inflammation, and repair may culminate in complete restoration of tissue and organ function. Conversely, persistent organ dysfunction may result from serious inflammation or damage to the local tissue structure caused by inflammation. Patients may present with ARDS, multiple-organ failure, DIC, shock, and death. According to Fajgenbaum *et al.*, cytokine storm may occur based on the following three criteria: elevated levels of circulating cytokines, acute systemic inflammatory symptoms, and either secondary organ dysfunction resulting from inflammation beyond that which could be attributed to a normal response to a pathogen (if present) or any cytokine-driven organ dysfunction (if no pathogen is present) [48].

Highly pathogenic coronaviruses may trigger cytokine storm [7,72,73]. Rapid viral replication and excessive proinflammatory cytokine/chemokine production may lead to the apoptosis of respiratory epithelial and endothelial cells [74,75]. The mechanism underlying this apoptosis involves the Fas/FasL or tumor necrosis factor-related apoptosis-inducing ligand/death receptor 5 pathway caused by IFN- $\alpha\beta$ and IFN- γ -induced inflammatory cell infiltration [76–81]. Inflammation then leads to extensive pulmonary congestion and edema as well as the formation of hyaline membrane in the alveolar

cavity, causing intractable hypoxemia and respiratory distress, which was known as ARDS [82,83]. Histopathological findings of the lungs revealed diffuse alveolar damage and infiltration of interstitial or intra-alveolar inflammatory cells in patients diagnosed with 2009 influenza A (H1N1) [84]. Similar pathological features can also be observed in SARS, MERS, and COVID-19 [36,85,86]. In addition, excess cytokines can diffuse into the circulatory system and cause systemic inflammatory response syndrome. The collateral damage of the immune response caused by cytokines may pose a more lethal threat than the pathogen itself. Therefore, identifying and blocking the cytokine pathways that cause the inflammatory storm are critical to reducing the rates of serious illness and mortality.

Cytokine storm in highly pathogenic coronaviruses

Coronaviruses are a group of highly infectious and pathogenic viruses that have attracted global attention. They belong to the category of enveloped, positive-sense, single-stranded RNA viruses, which are classified into two varieties: low-pathogenicity and high-pathogenicity coronaviruses [87,88]. The former infects the upper respiratory tract and causes mild symptoms, whereas highly pathogenic coronaviruses such as SARS-CoV [89], the Middle East respiratory syndrome coronavirus (MERS-CoV) [90], and SARS-CoV-2 [1] likely invade the lower respiratory tract, leading to the development of severe pneumonia associated with cytokine storm [87,91].

In 2002, the emergence of SARS, a highly contagious illness caused by SARS-CoV and first appeared in China, had significant global implications [92]. The autopsy report revealed diffuse alveolar damage [93,94]. The presence of hemophagocytic syndromes supported the hypothesis of cytokine dysregulation [94]. IL-6, IL-8, and TNF- α were among the initial cytokines that exhibit rapid elevation in the blood during early stages of infection [95]. The induction of IP10 and IL-2, as well as the consequent overproduction of IL-6 and the lack of IL-10 production, was a critical event in initiating immune-mediated acute lung injury and lymphocyte apoptosis [96]. In addition, chemokines, such as CCL2, CCL3, CCL5, CCL10, and CXCL10, were significantly upregulated at 24 h [97–99]. High levels of cytokines (IL-1, IL-6, IL-12, IL-18, IFN- γ , and TGF β) and chemokines (IL-8, CCL2, CXCL9, and CXCL10) were detected in patients severely infected with SARS compared with those with uncomplicated cases [96,100,101]. The pathogenesis of SARS could be attributed to dysregulation in the production of IFN- α and IFN- γ , as well as the transcription of IFN-stimulated genes [100,102,103].

MERS, caused by MERS-CoV, primarily occurred in Saudi Arabia and became endemic in 2012 [104]. Similar

to SARS, autopsy results revealed that diffuse alveolar damage was the most characteristic manifestation of MERS lungs [86]. An *in vitro* study revealed that MERS-CoV infection induced higher levels of IL-8, IL-12, IFN- γ , CCL2, CCL3, CCL5, and CXCL10 compared with SARS-CoV, whereas TNF- α and IL-6 levels were comparable between the two viruses [73]. The cytokine profiles of MERS in plasma samples were analyzed using cytometric bead array, showing a significant upregulation in IFN- α 2, IFN- γ , IL-10, TNF- α , IL-15, and IL-17 compared with the healthy controls [105]. Elevated levels of IL-6 and CXCL10 were detected in patients infected with MERS-CoV, which may be associated with the severity of pneumonia [106]. Upon infecting the human airway epithelial cells, analysis of mRNA expression of eight cytokines revealed that MERS-CoV induced a delayed yet significant induction of IL-1 β , IL-6, and IL-8 compared with SARS-CoV [107].

COVID-19, caused by another β -coronavirus known as SARS-CoV-2, was declared a pandemic in March 2020 [108]. Bilateral diffuse alveolar damage with infiltration of mononuclear inflammatory lymphocytes was observed in biopsy samples obtained postmortem from a patient who succumbed to severe COVID-19 [36], indicating the occurrence of cytokine storm. A previous study of 41 cases in Wuhan found that patients infected with SARS-CoV-2 exhibited higher levels of IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, IP10, TNF- α , IFN- γ , basic FGF, G-CSF, GM-CSF, MCP1, MIP1A, MIP1B, PDGF, and VEGF concentrations in their plasma compared with non-infected individuals. Meanwhile, in patients admitted to an ICU as opposed to non-ICU ones, the levels of IL-2, IL-7, IL-10, TNF- α , G-CSF, MCP1, MIP1A, and IP10 were high [7]. Xiong *et al.* observed significantly elevated expression levels of CXCL1, CXCL2, CXCL6, CXCL8, CXCL10, CCL2, CCL3, and CCL4 in the bronchoalveolar lavage fluid of patients with COVID-19 compared with the control group [109]. Furthermore, high levels of CCL2, CXCL2, CXCL8, and CXCL10 can facilitate the recruitment of immune cells to the infection site, potentially leading to exacerbating lung inflammation [109–111]. IL-6, IL-17, TNF- α , TGF- β , IFN, and CXCL10 may contribute to lung injury following SARS-CoV-2 infection [112]. Analysis of the immunopathology of SARS-CoV-2 conducted by Zhou *et al.* indicated that excessive activation of the immune response was likely responsible for acute pulmonary injury following SARS-CoV-2 infections [33].

Elevated levels of IL-6 in COVID-19

IL-6 is a pleiotropic cytokine secreted by various cell types. As a pyrogen, the diverse functions of IL-6 include increasing antibody production and inducing the

expression of acute-phase reactants [48]. SARS-CoV-2 infection of diverse immune cells, including monocytes, macrophages, dendritic cells, and T cells, results in their activation and secretion of IL-6 (Fig. 1) [33,113–118]. The activation of the NF- κ B pathway mediated by TLRs, as well as IL-1, IL-18, and TNF, is a strong stimulator of IL-6 synthesis [119–122]. However, excess IL-6 may also suppress IL-1 on the level of transcription [123].

IL-6 has two primary signal transduction pathways (Fig. 1). Classic *cis*-signaling via the membrane-bound IL-6 receptor (mIL-6R) is primarily anti-inflammatory, whereas *trans*-signaling via soluble IL-6R (sIL-6R) is rather pro-inflammatory [124]. This complex subsequently binds to gp130 on the cell membrane and then activates downstream signal transduction pathways, including the JAK-STAT3 pathway and JAK-SH2 domain tyrosine phosphatase 2 (SHP2)-mitogen-activated protein kinase pathway [125–128]. Then, a cascade of signaling events is started, promoting the transcription of multiple downstream genes and controlling the production of proteins implicated in the regulation of gene expression. As a warning signal during viral infection, IL-6 was thought to be related to antiviral activity, promoting inflammation resolution and tissue remodeling [129–131]. However, a study has indicated that high levels of IL-6 following viral infection promoted the generation of pathogenic Th17 cells capable of producing IL-17. The synergistic effect of IL-6 and IL-17 may impact the host's immune defense mechanism, leading to a persistent state of viral infection [132]. Elevated levels of IL-6 were detected in patients and mouse models who developed cytokine release syndrome following CAR T cell therapy [133–135], highlighting the pivotal role of this cytokine in the pathogenesis of cytokine storm.

A number of studies have found that patients with COVID-19, particularly those with serious conditions, have high expression of IL-6 [6,7,33,35,136–138]. Meta-analysis of six studies has found that patients with complicated COVID-19 (defined as ARDS, requiring ICU admission, or classified as severe or critical cases) had IL-6 levels 2.90-fold higher than those with non-complicated disease [138]. The findings of another meta-analysis have demonstrated a correlation among elevated IL-6 levels, disease progression, and an increased risk of mortality [139]. They also proposed employing a cut-off value of more than 55 and 80 pg/mL for IL-6 to identify patients at high risk of severe disease and mortality, respectively [139]. These reports have provided evidence for the significance of IL-6 as a biomarker for assessing disease severity and predicting death, as well as its involvement in COVID-19 pathogenicity. However, Yin *et al.* have demonstrated that increased levels of IL-6 may also serve as a predictive marker for long COVID-19,




Fig. 1 Cell signaling pathways of overactivated IL-6 in COVID-19. SARS-CoV-2 infection induces the activation of diverse immune cells, including monocytes, macrophages, dendritic cells, and T cells, leading to the secretion of interleukin-6 (IL-6). IL-6 receptor (IL-6R) has two forms: membrane-bound interleukin-6 receptor (mIL-6R) and soluble interleukin-6 receptor (sIL-6R). The formation of a complex between IL-6 and mIL-6R or sIL-6R is followed by its subsequent binding to gp130 on the cell membrane. The overproduction of IL-6 initiates a cascade of signaling transduction through classic *cis*- and *trans*-signaling pathways, thereby inciting a cytokine storm and contributing to an immune disorder in severe COVID-19. As a recombinant humanized monoclonal antibody, tocilizumab can specifically target mIL-6R and sIL-6R, thereby interfering with *cis*- and *trans*-signaling pathways to block signal transduction and attenuate cytokine storm.

with an average value of 20.92 pg/mL (compared with the mean value of 5.186 pg/mL in healthy individuals) [140]. The dysregulation of the immune response to COVID-19 has been reported to contribute to the involvement of IL-6. On the one hand, IL-6 may interfere with antiviral defenses by inducing dysfunction in NK cells and

inhibiting perforin and granzyme B [64,141]. On the other hand, the IL-6-mediated downregulation of HLA-DR expression on CD14 monocytes and lymphopenia was associated with sustained cytokine production and excessive inflammatory response [142]. IL-6 promotes the differentiation of T cells into Th17 cells and

subsequently inhibits the differentiation of regulatory T cells (T-reg), thereby disrupting the balance in T-reg/Th17 and contributing to the pathogenesis of ARDS [143]. Therefore, targeting IL-6 could serve as a promising therapy to prevent disease progression and mitigate mortality.

Tocilizumab for the treatment of COVID-19

Tocilizumab is a highly efficacious monoclonal antibody against IL-6R with remarkable specificity for sIL-6R and mIL-6R, thereby interfering with *cis*- and *trans*-signaling pathways to inhibit signal transduction (Fig. 1). Tocilizumab, which is initially approved as an orphan drug in Japan for the treatment of Castleman's disease in 2005 [144], has been licensed in the FDA for treating adult patients who have moderate-to-severe active rheumatoid arthritis and have had an inadequate response to disease-modifying anti-rheumatic drugs [145,146], giant cell arteritis [147,148], active polyarticular juvenile idiopathic arthritis [149], active systemic juvenile idiopathic arthritis [150,151], scleroderma-associated interstitial lung disease [152], and CAR T cell-induced severe or life-threatening cytokine release syndrome [40,42].

Based on the observed efficacy of tocilizumab in managing severe cytokine storm induced by CAR T cell therapy with elevated IL-6 levels, as well as analysis of the immune profile in patients with severe COVID-19 [33], we initiated a clinical investigation and registered a multicenter clinical trial (ChiCTR2000029765) in February 2020 to evaluate the effectiveness of tocilizumab in the treatment of patients with severe or critical COVID-19 [153,154]. In the initial uncontrolled trial, a total of 21 patients received tocilizumab at an initial dose ranging from 4 to 8 mg/kg body weight, with a recommended dosage of 400 mg administered intravenously up to a maximum of 800 mg. If fever occurred within a 12 h period, then an additional dose (same as before) should be administered. The cumulative dosage could not exceed two times the recommended amount. The findings of this study have indicated that tocilizumab could serve as a potential therapeutic intervention for COVID-19 because of its application potential in reducing cytokine storm and improving clinical symptoms such as body temperature, hypoxemia, and CT opacity changes. Following the publication of our retrospective report in the Proceedings of the National Academy of Sciences [153], Dr. Anthony L. Komaroff, the founding editor of NEJM Journal Watch and NEJM Journal Watch General Medicine, commended the impressive findings. Thus, further clinical trials are necessary to identify subsets of patients who are most likely to benefit from the drug [155]. On March 3, 2020, treatment with tocilizumab as a method of

immunotherapy was incorporated into the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia in China (7th Interim Edition) [156]. After 1 month, tocilizumab was recommended by the Infectious Diseases Society of America for clinical trials [157]. Similarly, the National Institutes of Health (NIH) moderately recommended tocilizumab for clinical trials in guidelines update on August 27, 2020 [158]. The progression of tocilizumab from basic research to clinical application is shown in Fig. 2. Subsequently, tocilizumab has been registered for clinical trials worldwide to evaluate its efficacy in SARS-CoV-2-induced inflammatory storm. Our administration protocols of tocilizumab, as described above, have served as a reference for almost all tocilizumab regimens in COVID-19, which are intended for short-term use. A search conducted on clinicaltrials.gov identified a total of 75 registered clinical trials evaluating the efficacy and safety of tocilizumab for COVID-19, with 29 having been completed to date.

Previous clinical trials have demonstrated the limited efficacy of tocilizumab in providing significant therapeutic benefits for patients with COVID-19 [159–165]. In a phase 3 trial of patients with severe COVID-19, tocilizumab has demonstrated no significant improvement in their clinical status or reduced mortality at 28 days [162]. Similar outcomes were observed in a randomized clinical trial of 126 hospitalized patients with COVID-19 with a PaO₂/FiO₂ ratio ranging from 200 to 300 mmHg [166]. Clinical deterioration was observed in 28.3% of patients treated with tocilizumab within 14 days, as compared with 27.0% in the standard care group. Another trial has shown a 17% mortality rate at 15 days among patients in the tocilizumab group compared with 3% in the standard care group, indicating that the administration of tocilizumab may increase mortality in severe or critical COVID-19 cases [167]. These findings may be attributed to various factors, including small samples size, patient demographics (such as disease severity, systemic inflammation levels, age, and comorbidities), lack of blinding procedures, and the absence of standardized treatment across trial sites and countries.

However, clinical studies have observed that tocilizumab induced a prompt and sustained response and was associated with a significant clinical improvement [168]. Snow *et al.* have carried out an analytical report to evaluate the therapeutic value of tocilizumab in COVID-19 [169]. The findings indicated that tocilizumab was associated with a decreased requirement for mechanical ventilation (8.7% vs. 10.5%, $P = 0.004$) on conventional analysis alone and a reduced progression-to-severe disease (28.9% vs. 36.6%, $P = 0.002$) compared with standard care. Another meta-analysis, comprising 52 studies with 27 004 patients, has found that tocilizumab exhibited an important survival benefit (11% in




Fig. 2 Timeline of tocilizumab from basic research discovery to clinical application in COVID-19. ^aThis article was published in the National Science Review [33]. ^bXu *et al.* initiated a clinical exploration and reported the benefits in PNAS [153], while registering a multicenter clinical trial (ChiCTR2000029765) to evaluate the efficacy of tocilizumab for patients with severe COVID-19. ^cAccording to Xu's report, tocilizumab was recommended by IDSA within the context of a clinical trial [157], with 75 registered trials available on clinicaltrials.gov to date. ^dThis article was initially preprinted in medRxiv on June 30, 2021 and subsequently published in BMJ Medicine [178]. ^eThis article was published online in JAMA on July 6, 2021 [183]. IL-6, interleukin-6; NHC, National Health Commission; IDSA, Infectious Diseases Society of America; PNAS, Proceedings of the National Academy of Sciences; NIH, National Institutes of Health; NHS, National Health Service; FDA, Food and Drug Administration; NMA, network meta-analysis; PMA, prospective meta-analysis; WHO, World Health Organization; JAMA, Journal of the American Medical Association.

randomized controlled trials (RCTs); 31% in observational studies) [170]. Moreover, the requirement for invasive mechanical ventilation was reduced by 19% in RCTs. Based on the RECOVERY trial [171], tocilizumab was related to a higher likelihood of hospital discharge within 28 days and a significant reduction in 28-day mortality compared with the usual care groups. Among patients who were not receiving invasive mechanical ventilation at randomization, tocilizumab decreased the probability of progression to the composite outcome of invasive mechanical ventilation or death. The median duration of hospitalization following early administration of tocilizumab was 9 days, which represented a significant reduction compared with the control group where the median length of stay was 12 days [172]. The improvements have been observed in the levels of ferritin, C-reactive protein, and D-dimer, as well as PaO₂/FiO₂ ratios after tocilizumab administration [168,172–176]. Furthermore, Wang *et al.* have found that treatment with tocilizumab in patients presenting bilateral pulmonary lesions and elevated IL-6 levels was associated with a prompt improvement of hypoxemia and a reduced requirement for increased oxygen inhalation [154]. The use of tocilizumab was identified as an independent predictor of survival in patients with severe COVID-19 and persistent hypoxia based on a retrospective cohort study [177]. The administration of tocilizumab within 6 days from admission may increase the probability of survival [173]. The previously mentioned studies have emphasized the critical significance of the early administration of tocilizumab in the course of disease progression. Moreover, network

meta-analysis has suggested that the combination of tocilizumab and corticosteroids likely resulted in reduced mortality compared with the use of corticosteroids alone [178]. Therefore, patients may derive greater therapeutic benefits.

The potential occurrence of adverse events warrants caution. Several clinical trials have concerned about the safety of tocilizumab in treating COVID-19. The most frequently reported adverse reactions included secondary infection, hepatic function abnormality, and neutropenia [159,165–167,171]. Rossotti *et al.* have observed a significantly higher incidence of severe infections exceeding 10%, which may lead to prolonged hospitalization [179]. Contrary to its repeated administration for the treatment of rheumatoid arthritis, tocilizumab was mostly administered as a single dose over a short period in patients with COVID-19 [180]. Some adverse reactions, such as neutropenia, were believed to be associated with the repeated administration of tocilizumab over a longer follow-up period [179]. The evidence of serious adverse events and the risk of bacterial or fungal infections by the WHO were rated as very low and low, respectively [181].

Based on the results from clinical trials, the National Health Service of the UK issued a recommendation on January 7, 2021, endorsing the use of tocilizumab as a therapeutic intervention for patients with COVID-19 admitted to the ICU [182]. In the fifth version of the WHO living guideline, published on July 6, 2021, a strong recommendation was made for tocilizumab in treating severe or critical COVID-19 patients [44]. This recommendation was primarily supported by network

meta-analysis [178] and a prospective meta-analysis [183]. The findings of these studies have demonstrated that patients treated with IL-6 receptor blockers exhibited a significantly reduced mortality rate. The GRADE assessment rated this outcome as high certainty. According to the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock guideline, which analyzed data from 15 RCTs involving 8318 patients with moderate or severe COVID-19, tocilizumab demonstrated potential efficacy in reducing the all-cause mortality by 32 ‰ and 16 ‰ among moderate and severe patients, respectively, on day 28. In addition, an increase of 35 ‰ and 12 ‰ was observed in clinical improvement of patients with moderate and

severe COVID-19, respectively [184]. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) also performed a review of several RCTs to access the efficacy and safety of tocilizumab for moderate or severe COVID-19 [185]. The results found that tocilizumab was related to a decrease in mortality and a reduced requirement for mechanical ventilation. The certainty of evidence regarding these findings was rated as moderate and high, respectively. Therefore, they recommend the use of tocilizumab for treating patients with severe COVID-19. Furthermore, tocilizumab has been widely recommended for global use. The recommendations for the use of tocilizumab from several official guidelines are presented in Table 1.

Table 1 Recommended guidelines and indications for the treatment of coronavirus disease 2019 (COVID-19) with tocilizumab

Organization	Conditions
China's NHC ^a (Updated on January 5, 2023)	Recommendation for severe and critical patients with significantly elevated IL-6 levels
WHO ^b (Updated on January 13, 2023)	Strong recommendation for severe or critical patients in combination with corticosteroids
IDSA ^c (Updated on June 26, 2023)	Conditional recommendation for severe or critical patients who exhibit elevated markers of systemic inflammation (low certainty of evidence)
Australian National Clinical Evidence Taskforce (Updated on May 30, 2023)	Conditional recommendation for patients (including adults, pregnant or breastfeeding women, children, and adolescents) who require supplemental oxygen, particularly in the presence of systemic inflammation
NICE ^d (Updated on August 9, 2023)	Recommendation for adult patients who are having systemic corticosteroids and need supplemental oxygen or MV ^e
NIH ^f (Updated on July 21, 2023)	Moderate recommendation for hospitalized patients who are receiving dexamethasone, have systemic inflammation, experience rapidly increasing oxygen needs, and require HFNC ^g oxygen, NIV ^h , MV ^e or ECMO ⁱ (moderate quality of evidence)
ESCMID ^j (Published online on November 21, 2021)	Recommendation for severe patients (quality of evidence: moderate for mortality, high for MV ^e)
J-SSCG 2020 Special Committee ^m (Updated in July 2022)	Weak recommendation for moderate patients who require oxygen/hospitalization (moderate certainty of evidence: GRADE 2B); weak recommendation for severe patients who require MV ^e /intensive care (low certainty of evidence: GRADE 2C)

Tocilizumab has gained widespread global recognition and is recommended in some official guidelines with specific indications for its use. The latest version of these guidelines is presented in the table. ^aNHC, National Health Commission; ^bWHO, World Health Organization; ^cIDSA, Infectious Diseases Society of America; ^dNICE, National Institute for Health and Care Excellence; ^eMV, mechanical ventilation; ^fNIH, National Institutes of Health; ^gHFNC, high-flow nasal cannula; ^hNIV, noninvasive ventilation; ⁱECMO, extracorporeal membrane oxygenation; ^jESCMID, European Society of Clinical Microbiology and Infectious Diseases; ^mJ-SSCG, Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock.

Conclusions

Cytokine storm can lead to the progression of COVID-19 into a highly inflammatory, as well as fatal, pulmonary and systemic disease. Therefore, timely intervention in cytokine over-release and cascade reactions is crucial for delaying disease progression and reducing mortality. Considering the pathogenic function of IL-6 signaling in the severe stage of COVID-19, tocilizumab exhibits potential efficacy for patients experiencing severe symptoms through improving clinical symptoms, decreasing requirement for mechanical ventilation, shortening the average length of hospitalization, and reducing the mortality rate. Tocilizumab has been widely recommended as a therapeutic option for severe COVID-19.

Compliance with ethics guidelines

Conflicts of interest Tiantian Li, Dongsheng Wang, Haiming Wei, and Xiaoling Xu declare that they have no conflicts of interest.

This manuscript is a review article and does not involve a research protocol that requires the approval of relevant institutional review board or ethics committee.

References

- Jiang S, Shi Z, Shu Y, Song J, Gao GF, Tan W, Guo D. A distinct name is needed for the new coronavirus. *Lancet* 2020; 395(10228): 949
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023. Available at the website of WHO

3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382(18): 1708–1720
4. Infectious Diseases Society of America. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2023. Available at the website of Infectious Diseases Society of America
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323(13): 1239–1242
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395(10223): 507–513
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497–506
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; 323(11): 1061–1069
9. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; 20(4): 425–434
10. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li S, Shan H, Jacobi A, Chung M. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology* 2020; 295(3): 200463
11. Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, Chen B, Zhang Z, Guan W, Ling Z, Jiang R, Hu T, Ding Y, Lin L, Gan Q, Luo L, Tang X, Liu J. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging* 2020; 47(5): 1275–1280
12. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front Med* 2020; 14(2): 185–192
13. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; 8(5): 475–481
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395(10229): 1054–1062
15. Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, Boscolo-Rizzo P. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. *JAMA* 2020; 323(20): 2089–2090
16. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol* 2020; 277(8): 2251–2261
17. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol* 2020; 5(7): 802–810
18. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and proposed management of the acute COVID-19 cardiovascular syndrome. *Circulation* 2020; 141(23): 1903–1914
19. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020; 17(5): 259–260
20. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV 3rd, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and cardiovascular disease: from bench to bedside. *Circ Res* 2021; 128(8): 1214–1236
21. Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. *J Clin Transl Hepatol* 2020; 8(1): 13–17
22. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther* 2020; 52(4): 584–599
23. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; 97(5): 829–838
24. Jansen J, Reimer KC, Nagai JS, Varghese FS, Overheul GJ, de Beer M, Rovers R, Daviran D, Fermin LAS, Willemsen B, Beukenboom M, Djurdjaj S, von Stillfried S, van Eijk LE, Mastik M, Bulthuis M, Dunnen WD, van Goor H, Hillebrands JL, Triana SH, Alexandrov T, Timm MC, van den Berge BT, van den Broek M, Nlandu Q, Heijnert J, Bindels EMJ, Hoogenboezem RM, Mooren F, Kuppe C, Miesen P, Grünberg K, Ijzermans T, Steenberg EJ, Czogalla J, Schreuder MF, Sommerdijk N, Akiva A, Boor P, Puelles VG, Floege J, Huber TB; COVID Moonshot consortium; van Rij RP, Costa IG, Schneider RK, Smeets B, Kramann R. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. *Cell Stem Cell* 2022; 29(2): 217–231.e8
25. Klok FA, Kruij MJHA, van der Meer NJM, Arbous MS,

- Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. *Thromb Res* 2020; 191: 148–150
26. De Rosa MA, Calisi D, Carrarini C, Mazzatenta A, Mattoli MV, Neri G, D'Ardes D, Giansante R, Onofri M, Stuppia L, Cipollone F, Bonanni L. Olfactory dysfunction as a predictor of the future development of parkinsonism in COVID-19 patients: a 18F-FDOPA PET study. *Eur J Neurodegener Dis* 2023; 12(1): January–April: 20–23
 27. Antoniadou E, Melissaris S, Panagopoulos D, Kalloniati E, Sfakianos G. Pathophysiology and neuroinflammation in COVID-19. *Eur J Neurodegener Dis* 2022; 11(1): January-June: 7–9
 28. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol* 2020; 77(6): 683–690
 29. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M, Anheim M, Meziani F. Neurologic features in severe SARS-CoV-2 infection. *N Engl J Med* 2020; 382(23): 2268–2270
 30. Aggarwal K, Agarwal A, Jaiswal N, Dahiya N, Ahuja A, Mahajan S, Tong L, Duggal M, Singh M, Agrawal R, Gupta V. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *PLoS One* 2020; 15(11): e0241661
 31. National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. 10th Interim Edition. 2023. Available at the website of National Health Commission of the People's Republic of China
 32. Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L, Yang M, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Gao GF, Jiang C, Liu L, Liu Y. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. *J Allergy Clin Immunol* 2020; 146(1): 119–127.e4
 33. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. *Natl Sci Rev* 2020; 7(6): 998–1002
 34. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. *Int J Infect Dis* 2020; 96: 131–135
 35. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). *Front Immunol* 2020; 11: 827
 36. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; 8(4): 420–422
 37. Davies R, Choy E. Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis. *Semin Immunol* 2014; 26(1): 97–104
 38. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. *Drugs Today (Barc)* 2006; 42(9): 559–576
 39. Nakahara H, Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. *Endocr Metab Immune Disord Drug Targets* 2006; 6(4): 373–381
 40. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist* 2018; 23(8): 943–947
 41. Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, Grupp SA, June CH, Melenhorst JJ, Lacey SF. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *J Immunol Methods* 2016; 434: 1–8
 42. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. *Expert Rev Clin Immunol* 2019; 15(8): 813–822
 43. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19. 2021. Available at the website of FDA
 44. World Health Organization. Therapeutics and COVID-19: living guideline. 2021. Available at the website of WHO
 45. Vilček J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. *Trends Pharmacol Sci* 2004; 25(4): 201–209
 46. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. *Microbiol Mol Biol Rev* 2012; 76(1): 16–32
 47. Cobb DA, Lee DW. Cytokine release syndrome biology and management. *Cancer J* 2021; 27(2): 119–125
 48. Fajgenbaum DC, June CH. Cytokine storm. *N Engl J Med* 2020; 383(23): 2255–2273
 49. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. *Transplant Proc* 1993; 25(1 Pt 2): 1216–1217
 50. Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. *Viruses* 2019; 11(10): 961
 51. MacCann R, Leon AAG, Gonzalez G, Carr MJ, Feeney ER, Yousif O, Cotter AG, de Barra E, Sadlier C, Doran P, Mallon PW. Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity. *Front Immunol* 2023; 14: 1166574
 52. Primorac D, Vrdoljak K, Brlek P, Pavelić E, Molnar V, Matišić V, Erceg Ivkošić I, Parčina M. Adaptive immune responses and immunity to SARS-CoV-2. *Front Immunol* 2022; 13: 848582
 53. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. *Immunology* 2021; 162(1): 30–43
 54. Chan L, Karimi N, Morovati S, Alizadeh K, Kakish JE, Vanderkamp S, Fazel F, Napoleoni C, Alizadeh K, Mehrani Y, Minott JA, Bridle BW, Karimi K. The roles of neutrophils in cytokine storms. *Viruses* 2021; 13(11): 2318
 55. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M,

- Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol* 2021; 21(5): 319–329
56. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, Jordan MB. Hemophagocytosis causes a consumptive anemia of inflammation. *J Exp Med* 2011; 208(6): 1203–1214
57. Conti P, Caraffa A, Tetè G, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Di Emidio P, Ronconi G. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. *J Biol Regul Homeost Agents* 2020; 34(5): 1629–1632
58. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, Kronbichler A, Shin JI. Immunopathogenesis and treatment of cytokine storm in COVID-19. *Theranostics* 2021; 11(1): 316–329
59. Teodoro AGF, Rodrigues WF, Farnesi-de-Assunção TS, Borges AVBE, Obata MMS, Neto JRDC, da Silva DAA, Andrade-Silva LE, Desidério CS, Costa-Madeira JC, Barbosa RM, Cunha ACCH, Pereira LQ, de Vito FB, Vaz Tanaka SCS, Helmo FR, Lemes MR, Barbosa LM, Trevisan RO, Mundim FV, Oliveira-Scussel ACM, Junior PRR, Monteiro IB, Ferreira YM, Machado GH, Ferreira-Paim K, Moraes-Souza H, de Oliveira CJF, Rodrigues Júnior V, Silva MVD. Inflammatory response and activation of coagulation after COVID-19 infection. *Viruses* 2023; 15(4): 938
60. Jing H, Wu X, Xiang M, Liu L, Novakovic VA, Shi J. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. *Front Immunol* 2022; 13: 992384
61. Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, Zaheer SA, Iyer SS, Burton C, James D, Zaheer A. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. *Neuroscientist* 2020; 26(5–6): 402–414
62. D'Ovidio C. The response of immune sentinels causing inflammation in glioma and glioblastoma. *Eur J Neurodegener Dis* 2023; 12(2): May–August: 46–50
63. Ghasemzadeh M, Ghasemzadeh A, Hosseini E. Exhausted NK cells and cytokine storms in COVID-19: whether NK cell therapy could be a therapeutic choice. *Hum Immunol* 2022; 83(1): 86–98
64. Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. *Arthritis Rheumatol* 2015; 67(11): 3037–3046
65. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. *Cytokine* 2015; 74(1): 5–17
66. Sallusto F. Heterogeneity of human CD4⁺ T cells against microbes. *Annu Rev Immunol* 2016; 34(1): 317–334
67. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, van den Akker JPC, Molenkamp R, Koopmans MPG, van Gorp ECM, Haagmans BL, de Swart RL, Sette A, de Vries RD. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* 2020; 5(48): eabd2071
68. Antonioli L, Fornai M, Pellegrini C, Blandizzi C. NKG2A and COVID-19: another brick in the wall. *Cell Mol Immunol* 2020; 17(6): 672–674
69. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020; 17(5): 533–535
70. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. *J Immunother Cancer* 2018; 6(1): 56
71. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014; 124(2): 188–195
72. Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J, Luo W, Chen T, Qin Q, Deng P. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. *Am J Respir Crit Care Med* 2005; 171(8): 850–857
73. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, Sun T, Lau CC, Wong KK, Chan JY, Chan JF, To KK, Chan KH, Zheng BJ, Yuen KY. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. *J Infect Dis* 2014; 209(9): 1331–1342
74. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, Sabzevari A, Azizi G. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. *Scand J Immunol* 2021; 93(4): e12998
75. Morris G, Bortolasci CC, Puri BK, Olive L, Marx W, O'Neil A, Athan E, Carvalho AF, Maes M, Walder K, Berk M. The pathophysiology of SARS-CoV-2: a suggested model and therapeutic approach. *Life Sci* 2020; 258: 118166
76. Perl M, Chung CS, Perl U, Lomas-Neira J, de Paepe M, Cioffi WG, Ayala A. Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. *Am J Respir Crit Care Med* 2007; 176(6): 591–601
77. Kitamura Y, Hashimoto S, Mizuta N, Kobayashi A, Kooguchi K, Fujiwara I, Nakajima H. Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. *Am J Respir Crit Care Med* 2001; 163(3): 762–769
78. Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S, Mack M, Kuziel WA, Corazza N, Brunner T, Seeger W, Lohmeyer J. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. *J Exp Med* 2008; 205(13): 3065–3077
79. Högnér K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlöhner S, Lewe-Schlosser P, Matrosovich M, Seeger W, Lohmeyer J, Herold S. Macrophage-expressed IFN- β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. *PLoS Pathog* 2013; 9(2): e1003188
80. Ishikawa E, Nakazawa M, Yoshinari M, Minami M. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. *J Virol* 2005; 79(12): 7658–7663
81. Sauler M, Bazan IS, Lee PJ. Cell death in the lung: the apoptosis-necroptosis axis. *Annu Rev Physiol* 2019; 81(1): 375–402
82. Laffey JG, Misak C, Kavanagh BP. Acute respiratory distress syndrome. *BMJ* 2017; 359: j5055

83. Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. *Int J Mol Sci* 2017; 18(2): 388
84. Nakajima N, Sato Y, Katano H, Hasegawa H, Kumasaka T, Hata S, Tanaka S, Amano T, Kasai T, Chong JM, Iizuka T, Nakazato I, Hino Y, Hamamatsu A, Horiguchi H, Tanaka T, Hasegawa A, Kanaya Y, Oku R, Oya T, Sata T. Histopathological and immunohistochemical findings of 20 autopsy cases with 2009 H1N1 virus infection. *Mod Pathol* 2012; 25(1): 1–13
85. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, Cai J, Li X, Kang W, Weng D, Lu Y, Wu D, He L, Yao K. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. *J Pathol* 2003; 200(3): 282–289
86. Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, Tong S, Tao Y, Alami NN, Haynes LM, Mutei MA, Abdel-Wareth L, Uyeki TM, Swerdlow DL, Barakat M, Zaki SR. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. *Am J Pathol* 2016; 186(3): 652–658
87. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017; 39(5): 529–539
88. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. *Nat Rev Drug Discov* 2016; 15(5): 327–347
89. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burgüiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003; 348(20): 1967–1976
90. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012; 367(19): 1814–1820
91. Kirtipal N, Bharadwaj S, Kang SG. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. *Infect Genet Evol* 2020; 85: 104502
92. World Health Organization. Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003. 2015. Available at the website of WHO
93. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS. Multiple organ infection and the pathogenesis of SARS. *J Exp Med* 2005; 202(3): 415–424
94. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* 2003; 361(9371): 1773–1778
95. Sheng WH, Chiang BL, Chang SC, Ho HN, Wang JT, Chen YC, Hsiao CH, Hsueh PR, Chie WC, Yang PC. Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome. *J Formos Med Assoc* 2005; 104(10): 715–723
96. Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirology* 2006; 11(6): 715–722
97. Cheung CY, Poon LL, Ng IH, Luk W, Sia SF, Wu MH, Chan KH, Yuen KY, Gordon S, Guan Y, Peiris JS. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages *in vitro*: possible relevance to pathogenesis. *J Virol* 2005; 79(12): 7819–7826
98. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, Nicholls JM, Peiris JS, Lau YL. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. *Blood* 2005; 106(7): 2366–2374
99. Yao Z, Zheng Z, Wu K, Junhua Z. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2. *Aging (Albany NY)* 2020; 12(9): 7639–7651
100. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY. An interferon- γ -related cytokine storm in SARS patients. *J Med Virol* 2005; 75(2): 185–194
101. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* 2004; 136(1): 95–103
102. Theron M, Huang KJ, Chen YW, Liu CC, Lei HY. A probable role for IFN- γ in the development of a lung immunopathology in SARS. *Cytokine* 2005; 32(1): 30–38
103. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ; Canadian SARS Research Network; Kelvin DJ. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. *J Virol* 2007; 81(16): 8692–8706
104. World Health Organization. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2023. Available at the website of WHO
105. Mahallawi WH, Khabour OF, Zhang Q, Makhdom HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine* 2018; 104: 8–13
106. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, Na SH, Kim M, Song KH, Bang JH, Park SW, Kim HB, Kim NJ, Oh MD. Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection. *J Korean Med Sci* 2016; 31(11): 1717–1725
107. Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, Chan JFW, Woo PCY, Yuen KY. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen Virol* 2013; 94(12): 2679–2690
108. Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 inflammatory syndrome. *Int J Mol Sci* 2020; 21(9): 3377
109. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y,

- Zhou Y, Lan K, Chen Y. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect* 2020; 9(1): 761–770
110. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M, Wang J. Heightened innate immune responses in the respiratory tract of COVID-19 patients. *Cell Host Microbe* 2020; 27(6): 883–890.e2
 111. Ichikawa A, Kuba K, Morita M, Chida S, Tezuka H, Hara H, Sasaki T, Ohteki T, Ranieri VM, dos Santos CC, Kawaoka Y, Akira S, Luster AD, Lu B, Penninger JM, Uhlig S, Slutsky AS, Imai Y. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. *Am J Respir Crit Care Med* 2013; 187(1): 65–77
 112. Khalil BA, Shakartalla SB, Goel S, Madkhana B, Halwani R, Maghazachi AA, AlSafar H, Al-Omari B, Al Bataineh MT. Immune profiling of COVID-19 in correlation with SARS and MERS. *Viruses* 2022; 14(1): 164
 113. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, Shi Y. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Immunology* 2020; 160(3): 261–268
 114. García-Nicolás O, Godel A, Zimmer G, Summerfield A. Macrophage phagocytosis of SARS-CoV-2-infected cells mediates potent plasmacytoid dendritic cell activation. *Cell Mol Immunol* 2023; 20(7): 835–849
 115. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I, Zhang S, Zhang Z. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat Med* 2020; 26(6): 842–844
 116. Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, Huang H, Mo Y, Luk TY, Lau TT, Yeung P, Chan WM, Wu AK, Lung KC, Tsang OT, Leung WS, Hung IF, Yuen KY, Chen Z. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. *Immunity* 2020; 53(4): 864–877.e5
 117. van der Sluis RM, Cham LB, Gris-Oliver A, Gammelgaard KR, Pedersen JG, Idorn M, Ahmadov U, Hernandez SS, Céralovic E, Godsk SH, Thyrsted J, Gunst JD, Nielsen SD, Jørgensen JJ, Bjerg TW, Laustsen A, Reinert LS, Olgarnier D, Bak RO, Kjolby M, Holm CK, Tolstrup M, Paludan SR, Kristensen LS, Søgaaard OS, Jakobsen MR. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. *EMBO J* 2022; 41(10): e109622
 118. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020; 368(6490): 473–474
 119. Mansell A, Jenkins BJ. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. *Cytokine Growth Factor Rev* 2013; 24(3): 249–256
 120. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. *Blood* 1991; 77(8): 1627–1652
 121. Netea MG, Kullberg BJ, Verschueren I, Van Der Meer JW. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. *Eur J Immunol* 2000; 30(10): 3057–3060
 122. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production *in vivo*. *Clin Immunol Immunopathol* 1989; 53(3): 488–498
 123. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. *Blood* 1990; 75(1): 40–47
 124. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta* 2011; 1813(5): 878–888
 125. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. *Blood* 1995; 86(4): 1243–1254
 126. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. *Immunity* 2019; 50(4): 1007–1023
 127. Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. *Proc Natl Acad Sci USA* 2013; 110(42): 16975–16980
 128. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. *Clin Sci (Lond)* 2012; 122(4): 143–159
 129. Bouezzedine F, Fardel O, Gripon P. Interleukin 6 inhibits HBV entry through NTCP down regulation. *Virology* 2015; 481: 34–42
 130. Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, Drew A, Bunn J, Suratt BT, Haynes L, Rincon M. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. *Mucosal Immunol* 2012; 5(3): 258–266
 131. Yang ML, Wang CT, Yang SJ, Leu CH, Chen SH, Wu CL, Shiau AL. IL-6 ameliorates acute lung injury in influenza virus infection. *Sci Rep* 2017; 7(1): 43829
 132. Hou W, Jin YH, Kang HS, Kim BS. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. *J Virol* 2014; 88(15): 8479–8489
 133. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov* 2016; 6(6): 664–679
 134. Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood* 2017; 130(21): 2295–2306
 135. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Dogliani C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. *Nat Med* 2018; 24(6): 739–748
 136. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response

- in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; 71(15): 762–768
137. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, Cheng J, Zhang X, Zhao Y, Xia Z, Zhang L, Wu G, Yi J. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. *EMBO Mol Med* 2020; 12(7): e12421
 138. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. *Rev Med Virol* 2020; 30(6): 1–9
 139. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. *J Med Virol* 2020; 92(11): 2283–2285
 140. Yin JX, Agbana YL, Sun ZS, Fei SW, Zhao HQ, Zhou XN, Chen JH, Kassegne K. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. *Infect Dis Poverty* 2023; 12(1): 43
 141. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, De Benedetti F, Behrens EM, Cron RQ, Nigrovic PA. On the alert for cytokine storm: immunopathology in COVID-19. *Arthritis Rheumatol* 2020; 72(7): 1059–1063
 142. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou M, Kyriakopoulou M, Dimopoulos G, Koutsodimitropoulos I, Velissaris D, Koufargyris P, Karageorgos A, Kattrini K, Lekakis V, Lupse M, Kotsaki A, Renieris G, Theodoulou D, Panou V, Koukaki E, Koulouris N, Gogos C, Koutsoukou A. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe* 2020; 27(6): 992–1000.e3
 143. Saki N, Javan M, Moghimian-Boroujeni B, Kast RE. Interesting effects of interleukins and immune cells on acute respiratory distress syndrome. *Clin Exp Med* 2023; 23(7): 2979–2996
 144. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. *Blood* 2005; 106(8): 2627–2632
 145. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008; 67(11): 1516–1523
 146. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* 2008; 58(10): 2968–2980
 147. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet* 2016; 387(10031): 1921–1927
 148. Stone JH, Klearman M, Collinson N. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med* 2017; 377(15): 1494–1495
 149. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Ann Rheum Dis* 2015; 74(6): 1110–1117
 150. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet* 2008; 371(9617): 998–1006
 151. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *N Engl J Med* 2012; 367(25): 2385–2395
 152. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2020; 8(10): 963–974
 153. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci USA* 2020; 117(20): 10970–10975
 154. Wang D, Fu B, Peng Z, Yang D, Han M, Li M, Yang Y, Yang T, Sun L, Li W, Shi W, Yao X, Ma Y, Xu F, Wang X, Chen J, Xia D, Sun Y, Dong L, Wang J, Zhu X, Zhang M, Zhou Y, Pan A, Hu X, Mei X, Wei H, Xu X. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. *Front Med* 2021; 15(3): 486–494
 155. Anthony L, Komaroff M. Tocilizumab Might Attenuate the “Cytokine Storm” in COVID-19 Patients. 2020. Available at the website of NEJM Journal Watch
 156. National Health Commission of the People’s Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia in China. 7th Interim Edition. 2020. Available at the website of National Health Commission of the People’s Republic of China
 157. Infectious Diseases Society of America. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020. Available at the website of Infectious Diseases Society of America
 158. National Institutes of Health. COVID-19 Treatment Guidelines. 2020. Available at the website of NIH

159. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in patients hospitalized with Covid-19 pneumonia. *N Engl J Med* 2021; 384(1): 20–30
160. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schragger H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yin JM, Bowman KA, Meyerowitz E, Zafar A, Drobní ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med* 2020; 383(24): 2333–2344
161. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021; 181(1): 32–40
162. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Kiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. *N Engl J Med* 2021; 384(16): 1503–1516
163. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, Montecucco C, Mojoli F, Giusti EM, Bruno R, The Covid Ircs San Matteo Pavia Task Force. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAAtteo COvid19 REgistry (SMACORE). *Microorganisms* 2020; 8(5): 695
164. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L; TOCI-RAF Study Group. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med* 2020; 76: 43–49
165. Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, Govil D, Deswal V, Chaudhry D, Singh PK, Gupta A, Agarwal V, Kumar S, Sangle SA, Chawla R, Narreddy S, Pandit R, Mishra V, Goel M, Ramanan AV. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. *Lancet Respir Med* 2021; 9(5): 511–521
166. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, Ballerini PF, Sciascia R, Zammarchi L, Para O, Scotton PG, Inojosa WO, Ravagnani V, Salerno ND, Sainaghi PP, Brignone A, Codeluppi M, Teopompi E, Milesi M, Bertomoro P, Claudio N, Salio M, Falcone M, Cenderello G, Donghi L, Del Bono V, Colombelli PL, Angheben A, Passaro A, Secondo G, Pascale R, Piazza I, Facciologno N, Costantini M; RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021; 181(1): 24–31
167. Veiga VC, Prats J, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum A, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintao MCT, Castro CG, Jr., Santos SV, de Almeida TML, Costa AN, Gebara OCE, de Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceicao FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, de Souza D, Cavalcanti AB, Scheinberg P; Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. *BMJ* 2021; 372: n84
168. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, De Peri E, Faletti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A, Modina D, Moiola G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E, Andreoli L, Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. *Autoimmun Rev* 2020; 19(7): 102568
169. Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. *Intensive Care Med* 2021; 47(6): 641–652
170. Kyriakopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: a systematic review and meta-analysis. *Respirology* 2021; 26(11): 1027–1040
171. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021; 397(10285): 1637–1645
172. Broman N, Feuth T, Vuorinen T, Valtonen M, Hohenthal U, Löyttyneimi E, Hirvioja T, Jalava-Karvinen P, Marttila H, Nordberg M, Oksi J. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study. *Clin Microbiol Infect* 2022; 28(6): 844–851
173. Sciascia S, Aprà F, Baffà A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol* 2020; 38(3): 529–532
174. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E,

- Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, Alcaraz-Serna A, Mateu-Albero T, Rodríguez-Cortes P, Sánchez-Cerrillo I, Esparcia L, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Suárez-Fernández C, Ancochea J, Canabal A, Albert P, Rodríguez-Serrano DA, Aguilar JM, Del Arco C, de Los Santos I, García-Fraile L, de la Cámara R, Serra JM, Ramírez E, Alonso T, Landete P, Soriano JB, Martín-Gayo E, Fraile Torres A, Zurita Cruz ND, García-Vicuña R, Cardeñoso L, Sánchez-Madrid F, Alfranca A, Muñoz-Calleja C, González-Álvoro I; REINMUN-COVID Group. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. *J Allergy Clin Immunol* 2021; 147(1): 72–80.e8
175. Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. COVIDOSE: a phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumonia. *Clin Pharmacol Ther* 2021; 109(3): 688–696
176. Hashimoto S, Yoshizaki K, Uno K, Kitajima H, Arai T, Tamura Y, Morishita H, Matsuoka H, Han Y, Minamoto S, Hirashima T, Yamada T, Kashiwa Y, Kameda M, Yamaguchi S, Tsuchihashi Y, Iwahashi M, Nakayama E, Shioda T, Nagai T, Tanaka T. Prompt reduction in CRP, IL-6, IFN- γ , IP-10, and MCP-1 and a relatively low basal ratio of ferritin/CRP is possibly associated with the efficacy of tocilizumab monotherapy in severely to critically ill patients with COVID-19. *Front Med (Lausanne)* 2021; 8: 734838
177. Gokhale Y, Mehta R, Kulkarni U, Karnik N, Gokhale S, Sundar U, Chavan S, Kor A, Thakur S, Trivedi T, Kumar N, Baveja S, Wadal A, Kolte S, Deolankar A, Pednekar S, Kalekar L, Padiyar R, Londhe C, Darole P, Pol S, Gokhe SB, Padwal N, Pandey D, Yadav D, Joshi A, Badgujar H, Trivedi M, Shah P, Bhavsar P. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India. *BMC Infect Dis* 2021; 21(1): 241
178. Zeraatkar D, Cusano E, Martínez JPD, Qasim A, Mangala S, Kum E, Bartoszko JJ, Devji T, Agoritsas T, Guyatt G, Izcovich A, Khamis AM, Lamontagne F, Rochweg B, Vandvik P, Brignardello-Petersen R, Siemieniuk RAC. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. *BMJ Med* 2022; 1(1): e000036
179. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, Bottiroli M, Mondino M, Merli M, Bellone A, Basile A, Ruggeri R, Colombo F, Moreno M, Pastori S, Perno CF, Tarsia P, Epis OM, Puoti M; Niguarda COVID-19 Working Group. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. *J Infect* 2020; 81(4): e11–e17
180. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A, Investigators AS. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013; 381(9877): 1541–1550
181. World Health Organization. Therapeutics and COVID-19: living guideline. 2023. Available at the website of WHO
182. National Health Service. NHS patients to receive life-saving COVID-19 treatments that could cut hospital time by 10 days. 2021. Available at the website of NHS
183. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuña R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. *JAMA* 2021; 326(6): 499–518
184. Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, Imura H, Okano H, Narita C, Mayumi T, Yasuda H, Yamada K, Yamada H, Kawasaki T, Shime N, Doi K, Egi M, Ogura H, Aihara M, Kushimoto S, Nishida O; Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (July 2022). *Acute Med Surg* 2022; 9(1): e789
185. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S, Verweij PE, Zollner-Schwetz I, Rodríguez-Baño J. ESCMID COVID-19 living guidelines: drug treatment and clinical management. *Clin Microbiol Infect* 2022; 28(2): 222–238